




# Quality Companies Within U.S. Health Care Can Endure Near-Term Worries

With a presidential election year looming, talk of U.S. health care reform is weighing on the sector.

July 2019

## KEY INSIGHTS

- More than a year out from the U.S. presidential election, health care is already shaping up to be one of the pivotal issues of the 2020 campaign.
- With Republican and Democratic Party presidential candidates favoring very different U.S. health care models, the uncertainty has seen the health care sector notably underperform in 2019.
- While volatility will likely remain a feature of the health care sector in the near term, we believe the fundamental quality of companies will drive long-term performance.




**Taymour Tamaddon**  
*Portfolio Manager, T. Rowe Price US Large-Cap Growth Equity Strategy*

The U.S. health care sector has endured a volatile 2019, in the crosshairs as the U.S. presidential election cycle gathers momentum. With more than a year until the election, health care is

shaping up to be one of the principal issues of the 2020 campaign. But while volatility will likely remain a feature in the near term, we believe the fundamental quality of companies will drive long-term performance.

## (Fig. 1) U.S. Health Care Has Notably Underperformed In 2019

The health care sector is once again at the mercy of the U.S. political cycle  
As of June 6, 2019



**Past Performance is not a reliable indicator of future performance.**

Source: Thomson Reuters Datastream. Copyright 2019 © Thomson Reuters. All rights reserved.

---

# USD 32 trillion<sup>1</sup>

Estimated additional health care spending required under a single-payer, Medicare for all model.

## What's Driving The Sector's Volatility?

Democratic candidates running for the 2020 election nomination favor a universal coverage system, although views diverge as to how best to achieve it. While some advocate for a single-payer system, others favor a combination of government-run and private health coverage. Republicans generally oppose a single-payer system, preferring a free market approach to health care reform with minimal government intervention. The uncertain political backdrop has hurt the health care sector in 2019 and is likely to continue as the election campaign progresses.

## Putting Near-Term Caution Into Perspective

For investors in health care, the biggest concern is the proposed single-payer "Medicare for all" model. Democratic Senator Bernie Sanders has been a particularly vocal advocate. While his sweeping reform plans might be construed as radical, they cannot be ruled out should he ultimately win his way to the White House in November 2020.

While we regard this outcome as a very low-probability event, the mere mention of such significant reforms has clouded the near-term outlook, adding an equity risk premium to the health care sector in general.

However, the long-term outlook should be put into perspective. A challenging chain of events would need to unfold before Bernie Sanders' proposal could become a reality. First, he must win the Democratic nomination to contest the presidential election and, subsequently, go on to win the vote to become the next U.S. president. Once in office, he would need to have majority Democratic Party support in both the Senate and the House of

Representatives in order to have any hope of enacting his radical health care plan. Finally, to fund the plan, he would need the vice president to sign off on roughly USD 32 trillion of additional health care expenditure on a budget-neutral basis, meaning the additional spending would have to be netted off against cuts made elsewhere.

The likelihood of so many stars aligning in this way is low, in our view. Nevertheless, as the political campaigning evolves and gathers pace over the next 12 to 18 months, we anticipate an ongoing degree of risk to be priced into the sector.

## Managed Care Companies Bearing The Brunt Of Uncertainty

The successful introduction of any single-payer, universal coverage system would see health management companies most significantly impacted, given that their entire business model would be made redundant. Consequently, the managed care subsector has been particularly volatile in 2019, despite the low probability of the outcome.

Under the current health care system, individual managed care companies negotiate lower health care costs, including cheaper prescription drugs, on behalf of customers. The proposed single-payer Medicare-for-all system would see the federal government negotiate directly on behalf of all Americans. This brings into play a powerful single payer with the potential to exercise its monopolistic buying power to dictate the price at which it buys drugs. The National Health Service in Great Britain demonstrates the potential of such a system—it pays less for prescription drugs than any other developed country. While good news for consumers, it would be bad news for pharmaceutical companies, which would be forced to accept lower prices for their products.

<sup>1</sup>Research by the Mercatus Center, George Mason University, as of July 30, 2018.

“Within health care, we look for companies that are major beneficiaries of durable secular trends—innovation in medical equipment/robotic technology is one such area of focus.

— **Taymour Tamaddon**

*Portfolio Manager,  
T. Rowe Price US Large-Cap  
Growth Equity Strategy*

### **In The U.S. Large-Cap Growth Portfolio, Fundamental Quality Matters Most**

From an investment perspective, the uncertain near-term environment does not deflect from our fundamental analysis of companies. With this intricate understanding of company quality as a starting point, we apply a probability framework that considers the likelihood of either a Republican or Democratic candidate becoming president and, similarly, the likelihood of the U.S. Senate and the House of Representatives being controlled by either party. We then overlay these scenarios onto the values of individual health care companies to determine if any discounts should be applied to each company and, in turn, which are discounting more, or less, risk than we think is probable.

Fine-tuning our exposure is admittedly more difficult in the current environment. While we have a constructive view of the health care sector over a three- to five-year horizon, it is difficult to anticipate exactly how the landscape might evolve over the next 12 to 18 months, as the election campaign unfolds.

Nevertheless, we can still be proactive in terms of our relative positioning. Through our fundamental analysis of companies, we have a good sense of which companies are being overly discounted and, similarly, which ones are not pricing in enough risk. This helps us to reprioritize the companies we own within the managed health care space on a relative basis—as opposed to trying to pick the best times to sell our exposure and then buy back into the sector at a later stage.

We maintain our conviction in the fundamental quality of certain managed care companies. This is an area where we have a deep insight into growth drivers that are underappreciated

by the market in general. Given this positive longer-term perspective, we are prepared to weather some volatility in the performance of these holdings over the coming 12 to 18 months.

### **Investing In Beneficiaries Of Long-Term, Secular Trends**

Within health care, we look for companies that are major beneficiaries of durable secular trends. Innovation in medical equipment and robotic technology is one such area of focus. Intuitive Surgical, a dominant player in the still relatively nascent robotic surgery market, is a good example. Intuitive's market-leading DaVinci surgical system is leading to vast improvements in clinical outcomes and patient recovery times, given the minimally invasive nature of the robot-assisted surgery—from orthopedic hip replacements, to cardiothoracic surgery, to neurosurgery. Robotics and technological advancement are revolutionizing patient treatment by providing precise, dexterous, and stable assistance to human surgery. We are witnessing a period of great change, and the penetration of robotics in the U.S. general surgery ecosystem is growing rapidly, driving higher revenues and earnings for leaders in this field.

Stryker is another attractive idiosyncratic story within the health care sector—an innovative company specializing in hip and knee replacement surgery. Its leading position in 3D printing of replacement hips and knees, together with its robotic technology, is similarly leading to dramatically better patient outcomes. As a result, Stryker is rapidly taking market share from competitors.

These are highly specialized, high-barrier businesses and, as such, are less exposed to the politically charged uncertainty that is evident in certain other areas in health care currently. Once the robotic equipment

is in place in a hospital, for example, and surgeons become skilled using it, these companies achieve “first mover” advantage because it is neither desirable nor efficient to buy new or upgraded equipment from a different

supplier. In this way, companies like Intuitive and Stryker become incumbent businesses, selling consumables and upgrades to the original piece of technology/equipment.

---

The specific securities identified and described do not represent all of the securities purchased, sold, or recommended for the portfolio, and no assumptions should be made that the securities identified and discussed were or will be profitable.

**Key Risks**—The following risks are materially relevant to the strategies highlighted in this material: transactions in securities of foreign currencies may be subject to fluctuations of exchange rates which may affect the value of an investment. The portfolio is subject to the volatility inherent in equity investing, and its value may fluctuate more than a fund investing in income-oriented securities.

T. Rowe Price focuses on delivering investment management excellence that investors can rely on—now and over the long term.

## T.RowePrice®

### Important Information

This material is being furnished for general informational purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, and prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. **Past performance is not a reliable indicator of future performance.** The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.

**Australia**—Issued in Australia by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. For Wholesale Clients only.

**Brunei**—This material can only be delivered to certain specific institutional investors for informational purpose upon request only. The strategy and/or any products associated with the strategy has not been authorised for distribution in Brunei. No distribution of this material to any member of the public in Brunei is permitted.

**Canada**—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.'s investment management services are only available to Accredited Investors as defined under National Instrument 45-106. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.

**China**—This material is provided to specific qualified domestic institutional investor or sovereign wealth fund on a one-on-one basis. No invitation to offer, or offer for, or sale of, the shares will be made in the People's Republic of China ("PRC") (which, for such purpose, does not include the Hong Kong or Macau Special Administrative Regions or Taiwan) or by any means that would be deemed public under the laws of the PRC. The information relating to the strategy contained in this material has not been submitted to or approved by the China Securities Regulatory Commission or any other relevant governmental authority in the PRC. The strategy and/or any product associated with the strategy may only be offered or sold to investors in the PRC that are expressly authorized under the laws and regulations of the PRC to buy and sell securities denominated in a currency other than the Renminbi (or RMB), which is the official currency of the PRC. Potential investors who are resident in the PRC are responsible for obtaining the required approvals from all relevant government authorities in the PRC, including, but not limited to, the State Administration of Foreign Exchange, before purchasing the shares. This document further does not constitute any securities or investment advice to citizens of the PRC, or nationals with permanent residence in the PRC, or to any corporation, partnership, or other entity incorporated or established in the PRC.

**DIFC**—Issued in the Dubai International Financial Centre by T. Rowe Price International Ltd. This material is only communicated on behalf of T. Rowe Price International Ltd. by its representative office which is regulated by the Dubai Financial Services Authority. For Professional Clients only.

**EEA ex-UK**—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.

**Hong Kong**—Issued in Hong Kong by T. Rowe Price Hong Kong Limited, 21/F, Jardine House, 1 Connaught Place, Central, Hong Kong. T. Rowe Price Hong Kong Limited is licensed and regulated by the Securities & Futures Commission. For Professional Investors only.

**Indonesia**—This material is intended to be used only by the designated recipient to whom T. Rowe Price delivered; it is for institutional use only. Under no circumstances should the material, in whole or in part, be copied, redistributed or shared, in any medium, without prior written consent from T. Rowe Price. No distribution of this material to members of the public in any jurisdiction is permitted.

**Korea**—This material is intended only to Qualified Professional Investors upon specific and unsolicited request and may not be reproduced in whole or in part nor can they be transmitted to any other person in the Republic of Korea.

**Malaysia**—This material can only be delivered to specific institutional investor upon specific and unsolicited request. The strategy and/or any products associated with the strategy has not been authorised for distribution in Malaysia. This material is solely for institutional use and for informational purposes only. This material does not provide investment advice or an offering to make, or an inducement or attempted inducement of any person to enter into or to offer to enter into, an agreement for or with a view to acquiring, disposing of, subscribing for or underwriting securities. Nothing in this material shall be considered a making available of, solicitation to buy, an offering for subscription or purchase or an invitation to subscribe for or purchase any securities, or any other product or service, to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the laws of Malaysia.

**New Zealand**—Issued in New Zealand by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013.

**Philippines**—THE STRATEGY AND/ OR ANY SECURITIES ASSOCIATED WITH THE STRATEGY BEING OFFERED OR SOLD HEREIN HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES REGULATION CODE. ANY FUTURE OFFER OR SALE OF THE STRATEGY AND/ OR ANY SECURITIES IS SUBJECT TO REGISTRATION REQUIREMENTS UNDER THE CODE, UNLESS SUCH OFFER OR SALE QUALIFIES AS AN EXEMPT TRANSACTION.

**Singapore**—Issued in Singapore by T. Rowe Price Singapore Private Ltd., No. 501 Orchard Rd, #10-02 Wheelock Place, Singapore 238880. T. Rowe Price Singapore Private Ltd. is licensed and regulated by the Monetary Authority of Singapore. For Institutional and Accredited Investors only.

**Switzerland**—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only.

**Taiwan**—This does not provide investment advice or recommendations. Nothing in this material shall be considered a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person in the Republic of China.

**Thailand**—This material has not been and will not be filed with or approved by the Securities Exchange Commission of Thailand or any other regulatory authority in Thailand. The material is provided solely to "institutional investors" as defined under relevant Thai laws and regulations. No distribution of this material to any member of the public in Thailand is permitted. Nothing in this material shall be considered a provision of service, or a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person where such provision, offer, solicitation, purchase or sale would be unlawful under relevant Thai laws and regulations.

**UK**—This material is issued and approved by T. Rowe Price International Ltd, 60 Queen Victoria Street, London, EC4N 4TZ which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.

**USA**—Issued in the USA by T. Rowe Price Associates, Inc., 100 East Pratt Street, Baltimore, MD, 21202, which is regulated by the U.S. Securities and Exchange Commission. For Institutional Investors only.

© 2019 T. Rowe Price. All rights reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/or apart, trademarks of T. Rowe Price Group, Inc.